West Pharmaceutical Services, Inc.
WST
$254.80
+0.82%
West Pharmaceutical Services is a key supplier of packaging components and containment solutions for the pharmaceutical and biotechnology industries. It is a leader in elastomer-based packaging and auto-injectors, with a strong international presence and a focus on proprietary products.…
WST
West Pharmaceutical Services, Inc.
$254.80
Investment Opinion: Should I buy WST Today?
Based on a synthesis of the provided data, the objective assessment for WST is a Hold. The company possesses undeniable strengths: a leading market position, solid financials, and consistent growth. However, these positives are currently offset by a high valuation, as reflected in its elevated P/E and P/S ratios, and recent technical underperformance. The stock does not appear sufficiently undervalued to warrant an aggressive Buy rating at this level, but its strong fundamentals prevent a Sell recommendation. Investors already holding positions may consider maintaining them, while new investors might wait for a more attractive entry point or clearer signs of margin re-expansion and sustained momentum.
Sign up to view all
WST 12-Month Price Forecast
The analysis indicates a fundamentally sound company trading at a premium price. The near-term path is balanced between growth execution and valuation risk, leading to a neutral stance with medium confidence.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services, Inc.'s 12-month outlook, with a consensus price target around $331.24 and implied upside of +30.0% versus the current price.
Average Target
$331.24
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$204 - $331
Analyst target range
Data not available. The provided analyst data includes estimated EPS and revenue but does not contain consensus target prices or a ratings distribution summary. The institutional ratings list shows recent actions from firms like Barclays (Equal Weight), Evercore ISI (Outperform), and UBS (Buy), but no sufficient quantitative consensus data is provided for a comprehensive summary.
Bulls vs Bears: WST Investment Factors
West Pharmaceutical Services exhibits a strong fundamental foundation with leadership in a niche market, consistent growth, and excellent financial health. However, the stock faces headwinds from high valuation multiples, recent underperformance, and margin pressures. The balance between these factors suggests a cautious but potentially rewarding investment for those with a longer-term horizon.
Bullish
- Strong Market Position: Leader in elastomer packaging and auto-injectors for high-growth injectable drug markets.
- Solid Financial Health: Low debt-to-equity (0.13), strong current ratio (3.02), and robust operating cash flow.
- Consistent Revenue Growth: Q4 2025 revenue grew 7.55% YoY, with high-margin proprietary products driving sales.
- Healthy Profitability Metrics: Net margin of 16.41%, ROE of 15.54%, and ROA of 10.09% indicate efficient operations.
Bearish
- High Valuation Multiples: Trailing P/E of 40.29 and forward P/E of 28.31 suggest premium pricing relative to earnings.
- Recent Price Underperformance: Stock down 8.24% over 6 months, underperforming SPY by 5.42 percentage points.
- Margin Compression: Net margin declined from 17.38% in Q4 2024 to 16.41% in Q4 2025.
- Elevated Short Interest: Short ratio of 3.07 indicates significant bearish sentiment among traders.
WST Technical Analysis
The stock's overall trend over the past six months has been negative, with the price declining from around $273 in early October 2025 to $250.64 as of March 31, 2026, representing a 6-month change of -8.24%. Short-term performance shows continued pressure, with the stock down 1.45% over the past month and down 8.90% over the past three months, underperforming the broader market (SPY) in both periods. The current price of $250.64 sits near the middle of its 52-week range ($187.43 to $322.34), indicating it has recovered from the lows seen in early 2026 but remains well below its yearly high.
Beta
1.18
1.18x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$187-$322
Price range past year
Annual Return
+15.0%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | +1.4% | -3.6% |
| 3m | -7.8% | -4.0% |
| 6m | -6.5% | -2.0% |
| 1y | +15.0% | +16.2% |
| ytd | -7.8% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
Revenue in Q4 2025 was $805 million, representing a 7.55% year-over-year growth from the same quarter in 2024. Profitability remains solid, with a net margin of 16.41% in Q4 2025, though it has moderated from the 17.38% net margin in Q4 2024. The company exhibits strong financial health, with a low debt-to-equity ratio of 0.13 and a robust current ratio of 3.02, supported by substantial operating cash flow of $251.1 million in the latest quarter. Operational efficiency is sound, with a Return on Equity (ROE) of 15.54% and a Return on Assets (ROA) of 10.09%, indicating effective use of shareholder capital and company assets.
Quarterly Revenue
$805000000.0B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$468900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 40.29, while the forward P/E is 28.31, suggesting the market expects earnings growth. The Price-to-Sales (P/S) ratio is 6.47 and the Enterprise Value-to-Sales (EV/Sales) is 5.72. Peer comparison data is not available in the provided inputs, so a relative valuation assessment cannot be made.
PE
40.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 30x~63x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risks for WST stem from its valuation and market sensitivity. The stock's high trailing P/E ratio of 40.29 and forward P/E of 28.31 make it vulnerable to multiple compression if earnings growth fails to meet elevated expectations. Furthermore, a short ratio of 3.07 reflects substantial skepticism in the near-term price trajectory, which could lead to increased volatility. Operationally, the company is exposed to the cyclicality of the pharmaceutical and biotech industries. Its revenue is tied to drug development pipelines, regulatory approvals, and capital expenditure cycles of its clients. Any slowdown in biopharmaceutical innovation or spending could directly impact demand for its packaging and delivery solutions. While the company's financials are robust, evidenced by a low debt load and strong liquidity, its premium valuation in a potentially slowing economic environment presents a key risk to investor capital.
FAQ
The key risks include valuation contraction if earnings growth slows, given its high P/E ratio. Sector cyclicality is a concern, as demand depends on pharmaceutical R&D spending. Recent price underperformance and a high short ratio of 3.07 also indicate near-term bearish sentiment and potential for increased volatility.
The 12-month outlook presents a base case target range of $250 to $285, assuming steady execution. A bull case, with a 25% probability, could see the stock reach $300-$322 (near its 52-week high) on strong catalysts. A bear case, with a 15% probability, could see it fall to $187-$230 (near its 52-week low) on earnings disappointment or a market downturn.
Based on traditional metrics, WST appears overvalued. Its trailing P/E ratio of 40.29 is high, and its Price-to-Sales ratio of 6.47 also indicates a premium. The forward P/E of 28.31 shows the market expects earnings growth to justify the price. While not extremely overvalued, it is priced for perfection, leaving little room for operational setbacks.
WST is a good stock for investors seeking exposure to the pharmaceutical supply chain, but timing is crucial. Its strong fundamentals, including a 15.54% ROE and 7.55% revenue growth, are positive. However, its high trailing P/E of 40.3 suggests it is not cheap. A 'Hold' rating is more appropriate currently, suggesting new buyers may want to wait for a better valuation entry point.
WST is more suitable for long-term investment. Its business model benefits from long-term trends in biologic and injectable drugs, and its financial strength supports sustained growth. The stock's high valuation and recent volatility make it less ideal for short-term trading, as it may require patience to realize its fundamental value.